Cancers bronchiques des non-fumeurs: particularités épidémiologiques, thérapeutiques et moléculaires

Julien Hadoux; Benjamin Besse; David Planchard

doi:10.1016/j.lpm.2011.02.001

Cancers bronchiques des non-fumeurs: particularités épidémiologiques, thérapeutiques et moléculaires

Translated title of the contribution: Lung cancer in never smoker: Epidemiology, molecular profiles and treatment

Julien Hadoux, Benjamin Besse, David Planchard

Research output: Contribution to journal › Short survey › peer-review

7 Citations (Scopus)

Abstract

Smoking status is essential to know when taking care of a lung cancer patient.Never-smoking patients account for 15% of lung cancer patients, more often women and adenocarcinoma.Environmental tobacco smoke and occupational exposure could be important risk factors.Lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics such as frequent EGFR mutations.New molecular targets are on investigation, such as EML4-ALK translocation.Treatment of lung cancer in never-smoker is getting different from that of smoker with more efficacy of molecular targeted therapies.

Translated title of the contribution	Lung cancer in never smoker: Epidemiology, molecular profiles and treatment
Original language	French
Pages (from-to)	371-378
Number of pages	8
Journal	Presse Medicale
Volume	40
Issue number	4 PART1
DOIs	https://doi.org/10.1016/j.lpm.2011.02.001
Publication status	Published - 1 Jan 2011

Access to Document

10.1016/j.lpm.2011.02.001

Cite this

@article{aa707d699d434506a72fb752456b18fa,

title = "Cancers bronchiques des non-fumeurs: particularit{\'e}s {\'e}pid{\'e}miologiques, th{\'e}rapeutiques et mol{\'e}culaires",

abstract = "Smoking status is essential to know when taking care of a lung cancer patient.Never-smoking patients account for 15% of lung cancer patients, more often women and adenocarcinoma.Environmental tobacco smoke and occupational exposure could be important risk factors.Lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics such as frequent EGFR mutations.New molecular targets are on investigation, such as EML4-ALK translocation.Treatment of lung cancer in never-smoker is getting different from that of smoker with more efficacy of molecular targeted therapies.",

author = "Julien Hadoux and Benjamin Besse and David Planchard",

year = "2011",

month = jan,

day = "1",

doi = "10.1016/j.lpm.2011.02.001",

language = "Fran{\c c}ais",

volume = "40",

pages = "371--378",

journal = "Presse Medicale",

issn = "0755-4982",

number = "4 PART1",

}

TY - JOUR

T1 - Cancers bronchiques des non-fumeurs

T2 - particularités épidémiologiques, thérapeutiques et moléculaires

AU - Hadoux, Julien

AU - Besse, Benjamin

AU - Planchard, David

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Smoking status is essential to know when taking care of a lung cancer patient.Never-smoking patients account for 15% of lung cancer patients, more often women and adenocarcinoma.Environmental tobacco smoke and occupational exposure could be important risk factors.Lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics such as frequent EGFR mutations.New molecular targets are on investigation, such as EML4-ALK translocation.Treatment of lung cancer in never-smoker is getting different from that of smoker with more efficacy of molecular targeted therapies.

AB - Smoking status is essential to know when taking care of a lung cancer patient.Never-smoking patients account for 15% of lung cancer patients, more often women and adenocarcinoma.Environmental tobacco smoke and occupational exposure could be important risk factors.Lung cancer in never-smoker appears to be a distinct entity from lung cancer in smoker, with specific molecular characteristics such as frequent EGFR mutations.New molecular targets are on investigation, such as EML4-ALK translocation.Treatment of lung cancer in never-smoker is getting different from that of smoker with more efficacy of molecular targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=79958850496&partnerID=8YFLogxK

U2 - 10.1016/j.lpm.2011.02.001

DO - 10.1016/j.lpm.2011.02.001

M3 - Brève enquête

C2 - 21420271

AN - SCOPUS:79958850496

SN - 0755-4982

VL - 40

SP - 371

EP - 378

JO - Presse Medicale

JF - Presse Medicale

IS - 4 PART1

ER -

Cancers bronchiques des non-fumeurs: particularités épidémiologiques, thérapeutiques et moléculaires

Abstract

Access to Document

Other files and links

Cite this